pharmaphorum
MAY 10, 2022
Roche has elevated a longstanding alliance with Finland’s Kaiku Health focusing on digital patient monitoring and management (DPMM) to the level of a strategic partnership. The two companies have been working together since 2019 on digital health interventions to provide support to people with cancer, focusing initially on tools for patients undergoing cancer immunotherapy.
NF2 BioSolutions
MAY 10, 2022
My name is Simon, I am 28 years old and my NF2 journey started back in 2013, it was one of my darkest times. It was a normal summers day in July 2013 and I had gone on a bike ride with my Auntie. I love cycling, the freedom of being outdoors in the fresh air. For some reason on this day I was having problems riding my bike, the track was narrow and I was finding it hard to keep the bike upright.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MAY 10, 2022
Researchers in the US have developed a wearable monitor that could be used to monitor metabolic diseases through gases released from a person’s skin. It’s a spin on the use of monitors that detect chemicals in sweat using electrical signals and has the key advantage that it does not need substantial amounts of sweat to get a reading, according to the team from Ohio State University.
Outsourcing Pharma
MAY 10, 2022
The US FDA released new draft guidance yesterday discussing, among other challenges, how unresolved product quality issues might be addressed in the context of regulatory decision-making.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MAY 10, 2022
Engaging, strategic, customer-centric communication is important in any industry, and no industry has been unaffected by the changing world of digital communication. But healthcare communicators have an extra layer of challenges as the conveyors of serious, important information that can also have a high degree of scientific complexity. “Healthcare can be incredibly complex.
Outsourcing Pharma
MAY 10, 2022
The clinical trial tech firm has announced a $220m Series D funding round which will boost its efforts to improve inclusivity and representation in studies.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Outsourcing Pharma
MAY 10, 2022
The CRO has paired with the drug discovery technology firm on Logica, an artificial intelligence tool designed to accelerate development of new treatments.
pharmaphorum
MAY 10, 2022
Not content with a $1.2 billion licensing deal for Biohaven Pharma’s oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer’s earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of the entire company will give it full ownership of the blockbuster-in-waiting, which pulled in $462 million in sales from the US market alone last year.
Pharma Times
MAY 10, 2022
NICE recommendation for Forxiga could entitle 53,000 adults to the new kidney disease therapy
pharmaphorum
MAY 10, 2022
Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer’s disease therapy lecanemab, which is now fully filed with the FDA. The two partners have also requested a priority review for the Biologics License Application (BLA) for lecanemab, which if granted by the FDA could result in an approval before the end of the year.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
MAY 10, 2022
Researchers reviewed findings from 158 global studies to determine how COVID-19 affects people living with diabetes
pharmaphorum
MAY 10, 2022
Administering a fourth dose of an mRNA COVID-19 vaccine provides a stronger level of protection than a third dose, particularly in the over-70s, according to the latest readout from the UK COV-BOOST trial. The trial showed that a second booster with the mRNA shots developed by Moderna and Pfizer/BioNTech given around seven months after the first booster is safe, and generates strong antibody and T-cell responses.
Expert insights. Personalized for you.
133 
Let's personalize your content